Melanie Turner1, Peter Murchie2, Sarah Derby3, Ariel Yuhan Ong4, Lauren Walji5, David McLernon2, Mary-Joan Macleod6, Rosalind Adam2. 1. Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. m.e.turner@abdn.ac.uk. 2. Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. 3. Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Bearsden, Glasgow, G61 1BD, UK. 4. Oxford Eye Hospital, Level Lg1 John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK. 5. University of Aberdeen Medical School, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. 6. Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK.
Abstract
PURPOSE: Existing research hints that people living with and beyond cancer are at an increased risk of stroke. However, there is insufficient evidence to appropriately inform guidelines for specific stroke prevention or management for cancer patients. We conducted a systematic review and meta-analysis to describe and quantify stroke incidence in people living with and beyond cancer. METHODS: Medline, CINAHL, and EMBASE were searched for epidemiological studies comparing stroke incidence between cancer and non-cancer patients. Reviewers independently extracted data; random-effects meta-analyses and quality assessment were performed. RESULTS: Thirty-six studies were narratively synthesised. Meta-analysis was conducted using seven studies. Methodological quality was high for most studies. Study populations were heterogeneous, and the length of follow-up and risk factors varied. There was a variation in risk between different cancer types and according to stroke type: pancreatic (HR 2.85 (95% CI 2.43-3.36), ischaemic) (HR 2.28 (95% CI 1.43-3.63), haemorrhagic); lung (HR 2.33 (95% CI 1.63-3.35), ischaemic) (HR 2.14 (95% CI 1.45-3.15), haemorrhagic); and head and neck (HR 1.54 (95% CI 1.40-1.69), haemorrhagic) cancers were associated with significantly increased incidence of stroke. Risk is highest within the first 6 months of diagnosis. Narrative synthesis indicated that several studies also showed significantly increased incidence of stroke in individuals with colorectal cancer, breast cancer, ovarian cancer, nasopharyngeal cancer, leukaemia, and myeloma, and those who have received radiotherapy for head and neck cancers and platinum-based chemotherapy may also have higher stroke incidence. CONCLUSIONS: Stroke incidence is significantly increased after diagnosis of certain cancers. IMPLICATIONS FOR CANCER SURVIVORS: Cardiovascular risk should be assessed during cancer survivorship care, with attention to modifying shared cancer/cardiovascular risk factors.
PURPOSE: Existing research hints that people living with and beyond cancer are at an increased risk of stroke. However, there is insufficient evidence to appropriately inform guidelines for specific stroke prevention or management for cancer patients. We conducted a systematic review and meta-analysis to describe and quantify stroke incidence in people living with and beyond cancer. METHODS: Medline, CINAHL, and EMBASE were searched for epidemiological studies comparing stroke incidence between cancer and non-cancer patients. Reviewers independently extracted data; random-effects meta-analyses and quality assessment were performed. RESULTS: Thirty-six studies were narratively synthesised. Meta-analysis was conducted using seven studies. Methodological quality was high for most studies. Study populations were heterogeneous, and the length of follow-up and risk factors varied. There was a variation in risk between different cancer types and according to stroke type: pancreatic (HR 2.85 (95% CI 2.43-3.36), ischaemic) (HR 2.28 (95% CI 1.43-3.63), haemorrhagic); lung (HR 2.33 (95% CI 1.63-3.35), ischaemic) (HR 2.14 (95% CI 1.45-3.15), haemorrhagic); and head and neck (HR 1.54 (95% CI 1.40-1.69), haemorrhagic) cancers were associated with significantly increased incidence of stroke. Risk is highest within the first 6 months of diagnosis. Narrative synthesis indicated that several studies also showed significantly increased incidence of stroke in individuals with colorectal cancer, breast cancer, ovarian cancer, nasopharyngeal cancer, leukaemia, and myeloma, and those who have received radiotherapy for head and neck cancers and platinum-based chemotherapy may also have higher stroke incidence. CONCLUSIONS: Stroke incidence is significantly increased after diagnosis of certain cancers. IMPLICATIONS FOR CANCER SURVIVORS: Cardiovascular risk should be assessed during cancer survivorship care, with attention to modifying shared cancer/cardiovascular risk factors.
Authors: Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Mitchell S V Elkind; Katherine S Panageas; Lisa M DeAngelis Journal: Ann Neurol Date: 2015-01-07 Impact factor: 10.422
Authors: Markus Kneihsl; Christian Enzinger; Gerit Wünsch; Michael Khalil; Valeriu Culea; Tadeja Urbanic-Purkart; Franz Payer; Kurt Niederkorn; Franz Fazekas; Thomas Gattringer Journal: J Neurol Date: 2015-11-03 Impact factor: 4.849
Authors: Nicholas G Zaorsky; Ying Zhang; Leila T Tchelebi; Heath B Mackley; Vernon M Chinchilli; Brad E Zacharia Journal: Nat Commun Date: 2019-11-15 Impact factor: 14.919
Authors: Dounya Schoormans; Pauline A J Vissers; Myrthe P P van Herk-Sukel; Johan Denollet; Susanne S Pedersen; Susanne O Dalton; Nina Rottmann; Lonneke van de Poll-Franse Journal: Cancer Med Date: 2018-09-15 Impact factor: 4.452
Authors: Georg Fuellen; Uwe Walter; Larissa Henze; Jan Böhmert; Daniel Palmer; Soyoung Lee; Clemens A Schmitt; Henrik Rudolf; Axel Kowald Journal: Cell Mol Neurobiol Date: 2022-08-11 Impact factor: 4.231